ACVR1, a therapeutic target of fibrodysplasia ossificans progressiva, is negatively regulated by miR-148a

International Journal of Molecular Sciences

Volumn 13, Issue 2, 2012, Pages 2063-2077

  Song, Hao ^a,b   Wang, Qi ^a   Wen, Junge ^b   Liu, Shunai ^a   Gao, Xuesong ^a   Cheng, Jun ^a   Zhang, Deli ^b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b NORTHWEST A F UNIVERSITY   (China)

Author keywords

ACVR1; BMP; EndMT; FOP; MiR 148a

Indexed keywords

ACTIVIN RECEPTOR 1; BONE MORPHOGENETIC PROTEIN; MESSENGER RNA; MICRORNA; MICRORNA 148A; UNCLASSIFIED DRUG; ACVR1 PROTEIN, HUMAN; MIRN148 MICRORNA, HUMAN;

3' UNTRANSLATED REGION; ACTIVIN RECEPTOR TYPE 1 GENE; ARTICLE; BINDING SITE; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION REGULATION; GENE REPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; OSSIFYING MYOSITIS; PROTEIN DNA BINDING; PROTEIN DNA INTERACTION; PROTEIN PROCESSING; PROTEIN TARGETING; QUANTITATIVE ANALYSIS; RECEPTOR GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ALIGNMENT; SITE DIRECTED MUTAGENESIS; UPREGULATION; WESTERN BLOTTING; GENETICS; HELA CELL LINE; MOLECULAR GENETICS; MOLECULARLY TARGETED THERAPY; MYOSITIS OSSIFICANS; NUCLEOTIDE SEQUENCE; PHYSIOLOGY; SEQUENCE HOMOLOGY; TUMOR CELL CULTURE;

ACTIVIN RECEPTORS, TYPE I; BASE SEQUENCE; GENE EXPRESSION REGULATION; HELA CELLS; HUMANS; MICRORNAS; MOLECULAR SEQUENCE DATA; MOLECULAR TARGETED THERAPY; MYOSITIS OSSIFICANS; SEQUENCE HOMOLOGY, NUCLEIC ACID; TUMOR CELLS, CULTURED;

EID: 84863232852     PISSN: None     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms13022063     Document Type: Article

References (59)

1. Kaplan, F.S.; LeMerrer, M.; Glaser, D.L.; Pignolo, R.J.; Goldsby, R.E.; Kitterman, J.A.; Groppe, J.; Shore, E.M. Fibrodysplasia ossificans progressiva. Best Pract. Res. Clin. Rheumatol. 2008, 22, 191-205.
2. Shore, E.M.; Xu, M.; Feldman, G.J.; Fenstermacher, D.A.; Cho, T.J.; Choi, I.H.; Connor, J.M.; Delai, P.; Glaser, D.L.; LeMerrer, M. et al. A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nature Genet. 2006, 38, 525-527.
3. Kaplan, F.S.; Xu, M.; Seemann, P.; Connor, J.M.; Glaser, D.L.; Carroll, L.; Delai, P.; Fastnacht-Urban, E.; Forman, S.J.; Gillessen-Kaesbach, G. et al. Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1. Hum. Mutat. 2009, 30, 379-390.
4. Bocciardi, R.; Bordo, D.; Di Duca, M.; Di Rocco, M.; Ravazzolo, R. Mutational analysis of the ACVR1 gene in Italian patients affected with fibrodysplasia ossificans progressiva: confirmations and advancements. Eur. J. Hum. Genet. 2009, 17, 311-318.
5. Lee, D.Y.; Cho, T.J.; Lee, H.R.; Park, M.S.; Yoo, W.J.; Chung, C.Y.; Choi, I.H. ACVR1 gene mutation in sporadic Korean patients with fibrodysplasia ossificans progressiva. J. Korean Med. Sci. 2009, 24, 433-437.
6. Petrie, K.A.; Lee, W.H.; Bullock, A.N.; Pointon, J.J.; Smith, R.; Russell, R.G.; Brown, M.A.; Wordsworth, B.P.; Triffitt, J.T. Novel mutations in ACVR1 result in atypical features in two fibrodysplasia ossificans progressiva patients. PLoS One 2009, 4, e5005.
7. Miyazono, K.; Maeda, S.; Imamura, T. BMP receptor signaling: Transcriptional targets, regulation of signals, and signaling cross-talk. Cytokine Growth Factor Rev. 2005, 16, 251-263.
8. Ruzinova, M.B.; Benezra, R. Id proteins in development, cell cycle and cancer. Trends Cell Biol. 2003, 13, 410-418.
9. Kowanetz, M.; Valcourt, U.; Bergstrom, R.; Heldin, C.H.; Moustakas, A. Id2 and Id3 Define the Potency of Cell Proliferation and Differentiation Responses to Transforming Growth Factor and Bone Morphogenetic Protein. Mol. Cell. Biol. 2004, 24, 4241-4254.
10. Hua, H.; Zhang, Y.Q.; Dabernat, S.; Kritzik, M.; Dietz, D.; Sterling, L.; Sarvetnick, N. BMP4 regulates pancreatic progenitor cell expansion through Id2. J. Biol. Chem. 2006, 281, 13574-13580.
11. Hollnagel, A.; Oehlmann, V.; Heymer, J.; Ruther, U.; Nordheim, A. Id genes are direct targets of bone morphogenetic protein induction in embryonic stem cells. J. Biol. Chem. 1999, 274, 19838-19845.
12. Du, Y.; Yip, H. Effects of bone morphogenetic protein 2 on Id expression and neuroblastoma cell differentiation. Differentiation 2010, 79, 84-92.
13. Peng, Y.; Kang, Q.; Luo, Q.; Jiang, W.; Si, W.K.; Liu, B.A.; Luu, H.H.; Park, J.K.; Li, X.M.; Luo, J. et al. Inhibitor of DNA binding/differentiation helix-loop-helix proteins mediate bone morphogenetic protein-induced osteoblast differentiation of mesenchymal stem cells. J. Biol. Chem. 2004, 279, 32941-32949.
14. van Dinther, M.; Visser, N.; de Gorter, D.J.; Doorn, J.; Goumans, M.J.; de Boer, J.; ten Dijke, P. ALK2 R206H mutation linked to fibrodysplasia ossificans progressiva confers constitutive activity to the BMP type I receptor and sensitizes mesenchymal cells to BMP-induced osteoblast differentiation and bone formation. J. Bone Miner. Res. 2010, 25, 1208-1215.
15. Medici, D.; Shore, E.M.; Lounev, V.Y.; Kaplan, F.S.; Kalluri, R.; Olsen, B.R. Conversion of vascular endothelial cells into multipotent stem-like cells. Nat. Med. 2010, 16, 1400-1406.
16. Bartel, D.P. MicroRNAs: Target recognition and regulatory functions. Cell 2009, 136, 215-233.
17. Guo, C.J.; Pan, Q.; Li, D.G.; Sun, H.; Liu, B.W. miR-15b and miR-16 are implicated in activation of the rat hepatic stellate cell: An essential role for apoptosis. J. Hepatol. 2009, 50, 766-778.
18. Goff, L.A.; Boucher, S.; Ricupero, C.L.; Fenstermacher, S.; Swerdel, M.; Chase, L.G.; Adams, C.C.; Chesnut, J.; Lakshmipathy, U.; Hart, R.P. Differentiating human multipotent mesenchymal stromal cells regulate microRNAs: Prediction of microRNA regulation by PDGF during osteogenesis. Exp. Hematol. 2008, 36, 1354-1369.
19. Chan, E.; Prado, D.E.; Weidhaas, J.B. Cancer microRNAs: From subtype profiling to predictors of response to therapy. Trends Mol. Med. 2011, 17, 235-243.
20. O'Connell, R.M.; Rao, D.S.; Chaudhuri, A.A.; Baltimore, D. Physiological and pathological roles for microRNAs in the immune system. Nat. Rev. Immunol. 2010, 10, 111-122.
21. Eskildsen, T.; Taipaleenmaki, H.; Stenvang, J.; Abdallah, B.M.; Ditzel, N.; Nossent, A.Y.; Bak, M.; Kauppinen, S.; Kassem, M. MicroRNA-138 regulates osteogenic differentiation of human stromal (mesenchymal) stem cells in vivo. Proc. Natl. Acad. Sci. USA 2011, 108, 6139-6144.
22. Gao, J.; Yang, T.; Han, J.; Yan, K.; Qiu, X.; Zhou, Y.; Fan, Q.; Ma, B. MicroRNA expression during osteogenic differentiation of human multipotent mesenchymal stromal cells from bone marrow. J. Cell. Biochem. 2011, 112, 1844-1856.
23. Karbiener, M.; Neuhold, C.; Opriessnig, P.; Prokesch, A.; Bogner-Strauss, J.G.; Scheideler, M. MicroRNA-30c promotes human adipocyte differentiation and co-represses PAI-1 and ALK2. RNA Biol. 2011, 8, 1-11.
24. Kota, J.; Chivukula, R.R.; O'Donnell, K.A.; Wentzel, E.A.; Montgomery, C.L.; Hwang, H.W.; Chang, T.C.; Vivekanandan, P.; Torbenson, M.; Clark, K.R. et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009, 137, 1005-1017.
25. Wiggins, J.F.; Ruffino, L.; Kelnar, K.; Omotola, M.; Patrawala, L.; Brown, D.; Bader, A.G. Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res. 2010, 70, 5923-5930.
26. Cheng, Y.; Liu, X.; Yang, J.; Lin, Y.; Xu, D.Z.; Lu, Q.; Deitch, E.A.; Huo, Y.; Delphin, E.S.; Zhang, C. MicroRNA-145, a novel smooth muscle cell phenotypic marker and modulator, controls vascular neointimal lesion formation. Circ. Res. 2009, 105, 158-166.
27. van Rooij, E.; Marshall, W.S.; Olson, E.N. Toward microRNA-based therapeutics for heart disease: The sense in antisense. Circ. Res. 2008, 103, 919-928.
28. Lo, H.L.; Chang, T.; Yam, P.; Marcovecchio, P.; Li, S.; Zaia, J.A.; Yee, J.K. Inhibition of HIV-1 replication with designed miRNAs expressed from RNA polymerase II promoters. Gene Ther. 2007, 14, 1503-1512.
29. Suzuki, T.; Sakurai, F.; Nakamura, S.-I.; Kouyama, E.; Kawabata, K.; Kondoh, M.; Yagi, K.; Mizuguchi, H. miR-122a-Regulated Expression of a Suicide Gene Prevents Hepatotoxicity Without Altering Antitumor Effects in Suicide Gene Therapy. Mol. Ther. 2008, 16, 1719-1726.
30. Chen, Y.; Zhu, X.; Zhang, X.; Liu, B.; Huang, L. Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. Mol. Ther. 2010, 18, 1650-1656.
31. Takeshita, F.; Patrawala, L.; Osaki, M.; Takahashi, R.U.; Yamamoto, Y.; Kosaka, N.; Kawamata, M.; Kelnar, K.; Bader, A.G.; Brown, D. et al. Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol. Ther. 2010, 18, 181-187.
32. Guo, S.L.; Peng, Z.; Yang, X.; Fan, K.J.; Ye, H.; Li, Z.H.; Wang, Y.; Xu, X.L.; Li, J.; Wang, Y.L. et al. miR-148a Promoted Cell Proliferation by Targeting p27 in Gastric Cancer Cells. Int. J. Biol. Sci. 2011, 7, 567-574.
33. Zhang, H.; Li, Y.; Huang, Q.; Ren, X.; Hu, H.; Sheng, H.; Lai, M. MiR-148a promotes apoptosis by targeting Bcl-2 in colorectal cancer. Cell Death Differ. 2011, 18, 1702-1710.
34. Duursma, A.M.; Kedde, M.; Schrier, M.; le Sage, C.; Agami, R. miR-148 targets human DNMT3b protein coding region. RNA 2008, 14, 872-877.
35. Pan, W.; Zhu, S.; Yuan, M.; Cui, H.; Wang, L.; Luo, X.; Li, J.; Zhou, H.; Tang, Y.; Shen, N. MicroRNA-21 and microRNA-148a contribute to DNA hypomethylation in lupus CD4+ T cells by directly and indirectly targeting DNA methyltransferase 1. J. Immunol. 2010, 184, 6773-6781.
36. Liu, X.G.; Zhan, Z.Z.; Xu, L.; Ma, F.; Li, D.; Guo, Z.H.; Li, N.; Cao, X.T. MicroRNA-148/152 Impair Innate Response and Antigen Presentation of TLR-Triggered Dendritic Cells by Targeting CaMKII alpha. J. Immunol. 2010, 185, 7244-7251.
37. Budhu, A.; Jia, H.L.; Forgues, M.; Liu, C.G.; Goldstein, D.; Lam, A.; Zanetti, K.A.; Ye, Q.H.; Qin, L.X.; Croce, C.M. et al. Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology 2008, 47, 897-907.
38. Giraud-Triboult, K.; Rochon-Beaucourt, C.; Nissan, X.; Champon, B.; Aubert, S.; Pietu, G. Combined mRNA and microRNA profiling reveals that miR-148a and miR-20b control human mesenchymal stem cell phenotype via EPAS1. Physiol. Genomics 2011, 43, 77-86.
39. Friedman, R.C.; Farh, K.K.-H.; Burge, C.B.; Bartel, D.P. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009, 19, 92-105.
40. John, B.; Enright, A.J.; Aravin, A.; Tuschl, T.; Sander, C.; Marks, D.S. Human MicroRNA targets. PLoS Biol. 2004, 2, 1862-1879.
41. Wang, X. miRDB: a microRNA target prediction and functional annotation database with a wiki interface. RNA 2008, 14, 1012-1017.
42. Girish, V.; Vijayalakshmi, A. Affordable image analysis using NIH Image/ImageJ. Indian J. Cancer 2004, 41, 47.
43. Izbicka, E.; Dunstan, C.R.; Horn, D.; Harris, M.; Harris, S.; Adams, R.; Mundy, G.R. Effects of human tumor cell lines on local new bone formation in vivo. Calcif. Tissue Int. 1997, 60, 210-215.
44. Kochanowska, I.E.; Wlodarski, K.; Wojtowicz, A.; Kinsner, A.; Ostrowski, K. BMP-4 and BMP-6 involvement in the osteogenic properties of the HeLa cell line. Exp. Biol. Med. 2002, 227, 57-62.
45. Kochanowska, I.E.; Wlodarski, K.; Wojtowicz, A.; Niemira, K.; Ostrowski, K. Osteogenic properties of various HeLa cell lines and the BMP family genes expression. Ann. Transplant. 2002, 7, 58-62.
46. Boylan, M.O.; Athanassiou, M.; Houle, B.; Wang, Y.; Zarbl, H. Activation of tumor suppressor genes in nontumorigenic revertants of the HeLa cervical carcinoma cell line. Cell Growth Differ. 1996, 7, 725-735.
47. Rashidi, H.; Strohbuecker, S.; Jackson, L.; Kalra, S.; Blake, A.J.; France, L.; Tufarelli, C.; Sottile, V. Differences in the Pattern and Regulation of Mineral Deposition in Human Cell Lines of Osteogenic and Non-Osteogenic Origin. Cells Tissues Organs 2011, doi:10.1159/000329861.
48. Majors, A.K.; Boehm, C.A.; Nitto, H.; Midura, R.J.; Muschler, G.F. Characterization of human bone marrow stromal cells with respect to osteoblastic differentiation. J. Orthop. Res. 1997, 15, 546-557.
49. Bielby, R.C.; Boccaccini, A.R.; Polak, J.M.; Buttery, L.D.K. In vitro differentiation and in vivo mineralization of osteogenic cells derived from human embryonic stem cells. Tissue Eng. 2004, 10, 1518-1525.
50. Manthey, C.; Mern, D.S.; Gutmann, A.; Zielinski, A.J.; Herz, C.; Lassmann, S.; Hasskarl, J. Elevated endogenous expression of the dominant negative basic helix-loop-helix protein ID1 correlates with significant centrosome abnormalities in human tumor cells. BMC Cell Biol. 2010, 11, doi:10.1186/1471-2121-11-2.
51. Obayashi, S.; Tabunoki, H.; Kim, S.U.; Satoh, J.-I. Gene Expression Profiling of Human Neural Progenitor Cells Following the Serum-Induced Astrocyte Differentiation. Cell. Mol. Neurobiol. 2009, 29, 423-438.
52. Zhang, J.F.; Fu, W.M.; He, M.L.; Xie, W.D.; Lv, Q.; Wan, G.; Li, G.; Wang, H.; Lu, G.; Hu, X. et al. MiRNA-20a promotes osteogenic differentiation of human mesenchymal stem cells by co-regulating BMP signaling. RNA Biol. 2011, 8, 829-838.
53. Wang, T.; Xu, Z. miR-27 promotes osteoblast differentiation by modulating Wnt signaling. Biochem. Biophys. Res. Commun. 2010, 402, 186-189.
54. Zhang, J.; Tu, Q.; Bonewald, L.F.; He, X.; Stein, G.; Lian, J.; Chen, J. Effects of miR-335-5p in modulating osteogenic differentiation by specifically downregulating Wnt antagonist DKK1. J. Bone Miner. Res. 2011, 26, 1953-1963.
55. Fasanaro, P.; Greco, S.; Ivan, M.; Capogrossi, M.C.; Martelli, F. microRNA: Emerging therapeutic targets in acute ischemic diseases. Pharmacol. Ther. 2010, 125, 92-104.
56. Kontorovich, T.; Levy, A.; Korostishevsky, M.; Nir, U.; Friedman, E. Single nucleotide polymorphisms in miRNA binding sites and miRNA genes as breast/ovarian cancer risk modifiers in Jewish high-risk women. Int. J. Cancer 2010, 127, 589-597.
57. Chin, L.J.; Ratner, E.; Leng, S.; Zhai, R.; Nallur, S.; Babar, I.; Muller, R.-U.; Straka, E.; Su, L.; Burki, E.A. et al. A SNP in a let-7 microRNA Complementary Site in the KRAS 3' Untranslated Region Increases Non-Small Cell Lung Cancer Risk. Cancer Res. 2008, 68, 8535-8540.
58. Catucci, I.; Yang, R.; Verderio, P.; Pizzamiglio, S.; Heesen, L.; Hemminki, K.; Sutter, C.; Wappenschmidt, B.; Dick, M.; Arnold, N. et al. Evaluation of SNPs in miR-146a, miR196a2 and miR-499 as Low-penetrance Alleles in German and Italian Familial Breast Cancer Cases. Hum. Mutat. 2010, 31, E1052-E1057.
59. Clop, A.; Marcq, F.; Takeda, H.; Pirottin, D.; Tordoir, X.; Bibe, B.; Bouix, J.; Caiment, F.; Elsen, J.M.; Eychenne, F. et al. A mutation creating a potential illegitimate microRNA target site in the myostatin gene affects muscularity in sheep. Nat. Genet. 2006, 38, 813-818.